These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 31958901)

  • 1. Anti-inflammatory Strategies for Schizophrenia: A Review of Evidence for Therapeutic Applications and Drug Repurposing.
    Hong J; Bang M
    Clin Psychopharmacol Neurosci; 2020 Feb; 18(1):10-24. PubMed ID: 31958901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Trials and Therapeutic Rationale for Drug Repurposing in Schizophrenia.
    Lago SG; Bahn S
    ACS Chem Neurosci; 2019 Jan; 10(1):58-78. PubMed ID: 29944339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in psychoneuroimmunology relevant to schizophrenia therapeutics.
    Debnath M; Venkatasubramanian G
    Curr Opin Psychiatry; 2013 Sep; 26(5):433-9. PubMed ID: 23867655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quetiapine : A Review of its Use in Schizophrenia.
    Gunasekara NS; Spencer CM
    CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammation, Antipsychotic Drugs, and Evidence for Effectiveness of Anti-inflammatory Agents in Schizophrenia.
    Pandurangi AK; Buckley PF
    Curr Top Behav Neurosci; 2020; 44():227-244. PubMed ID: 30993585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond.
    Meyer U; Schwarz MJ; Müller N
    Pharmacol Ther; 2011 Oct; 132(1):96-110. PubMed ID: 21704074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroinflammation and oxidative stress in schizophrenia: are these opportunities for repurposing?
    Ansari Z; Pawar S; Seetharaman R
    Postgrad Med; 2022 Mar; 134(2):187-199. PubMed ID: 34766870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential role of lamotrigine in schizophrenia.
    Large CH; Webster EL; Goff DC
    Psychopharmacology (Berl); 2005 Sep; 181(3):415-36. PubMed ID: 16001126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia.
    Tandon R; Belmaker RH; Gattaz WF; Lopez-Ibor JJ; Okasha A; Singh B; Stein DJ; Olie JP; Fleischhacker WW; Moeller HJ;
    Schizophr Res; 2008 Mar; 100(1-3):20-38. PubMed ID: 18243663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repurposing Drugs for Cognition in Schizophrenia.
    Yang YS; Marder SR; Green MF
    Clin Pharmacol Ther; 2017 Feb; 101(2):191-193. PubMed ID: 27706797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Drug-Repurposing-Driven Advances in the Discovery of Novel Antibiotics.
    Konreddy AK; Rani GU; Lee K; Choi Y
    Curr Med Chem; 2019; 26(28):5363-5388. PubMed ID: 29984648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabidiol Counteracts Amphetamine-Induced Neuronal and Behavioral Sensitization of the Mesolimbic Dopamine Pathway through a Novel mTOR/p70S6 Kinase Signaling Pathway.
    Renard J; Loureiro M; Rosen LG; Zunder J; de Oliveira C; Schmid S; Rushlow WJ; Laviolette SR
    J Neurosci; 2016 May; 36(18):5160-9. PubMed ID: 27147666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New antipsychotics and schizophrenia: a review on efficacy and side effects.
    Serretti A; De Ronchi D; Lorenzi C; Berardi D
    Curr Med Chem; 2004 Feb; 11(3):343-58. PubMed ID: 14965236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis.
    Sommer IE; de Witte L; Begemann M; Kahn RS
    J Clin Psychiatry; 2012 Apr; 73(4):414-9. PubMed ID: 22225599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repurposing psychiatric drugs as anti-cancer agents.
    Huang J; Zhao D; Liu Z; Liu F
    Cancer Lett; 2018 Apr; 419():257-265. PubMed ID: 29414306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses.
    Haddad PM; Correll CU
    Ther Adv Psychopharmacol; 2018 Nov; 8(11):303-318. PubMed ID: 30344997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence.
    Müller N
    Curr Opin Investig Drugs; 2010 Jan; 11(1):31-42. PubMed ID: 20047157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential of immune biomarkers to advance personalized medicine approaches for schizophrenia.
    Cox D; Chan MK; Bahn S
    J Nerv Ment Dis; 2015 May; 203(5):393-9. PubMed ID: 25919386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia.
    Na KS; Jung HY; Kim YK
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():277-86. PubMed ID: 23123365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-inflammatory strategies in the treatment of schizophrenia.
    Andrade C
    Expert Rev Clin Pharmacol; 2016; 9(2):161-3. PubMed ID: 26427750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.